6 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
rights reserved. 6 1. Global Liver Institute U.S. NASH Action Plan (Dec. 2020). 2. Cusi K. Diabetologia . 2016;59:1112 - 20. 3. Company estimates based … Liver Institute U.S. NASH Action Plan (Dec. 2020) Image sourced from: https://www.today.com/health/nonalcoholic - fatty - liver - disease - are - you
8-K
EX-99.1
AXLA
Axcella Health Inc.
10 Jan 22
Other Events
8:00am
rights reserved. 1. Desai, R. et al. Characterization of Polypharmacy in Patients with NAFLD. AASLD 2018 2. Global Liver Institute U.S. NASH Action Plan (Dec
8-K
EX-99.2
AXLA
Axcella Health Inc.
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
. Desai, R. et al. Characterization of Polypharmacy in Patients with NAFLD. AASLD 2018 2. Global Liver Institute U.S. NASH Action Plan (Dec. 2020). 3
- Prev
- 1
- Next